Clinical Trials Browser

Interventional × Carcinoid Tumor × Everolimus × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

100 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Phase 4 Completed

34 enrolled 8 charts

EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01263353 2020-12-21

COOPERATE-1

Phase 1 Completed

36 enrolled

Endocrine

Carcinoid Tumor

NCT00688623 2019-01-25

RAMSETE/CDE16

Phase 2 Completed

73 enrolled 13 charts

EndocrineNET

Carcinoid Tumor, Carcinoma, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1 Completed

22 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00412061 2014-11-21

RADIANT-2

Phase 3 Completed

429 enrolled 13 charts

Endocrine

Carcinoid Tumor, Carcinoma, Malignant Carcinoid Syndrome, Neoplasms

NCT01175096 2010-08-04

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Phase 1/2 Unknown

20 enrolled

EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Clinical Trials

ACTION-1

EVENET

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

COOPERATE-1

RAMSETE/CDE16

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

RADIANT-2

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor